Inflammatory Bowel Disease

The interim analysis of subcutaneous Entyvio demonstrates the treatment is safe and effective for long-term maintenance of ulcerative colitis, according to results presented at UEG Week.

Patients with Crohn’s disease improved sleep disturbance with a stepped-care approach that included brief behavioral therapy, according to study results.

Patients with ulcerative colitis who received Entyvio in routine practice experienced higher rates of remission than those treated with anti-TNF agents, according to study results.

Risk for developing inflammatory bowel disease was increased among first-degree relatives of individuals who already had the disease, according to study results.

Technology is always evolving and enacting change in the world of medicine.

In this exclusive video, Freddy Caldera, DO, MS, from the division of gastroenterology and hepatology at the University of Wisconsin School of Medicine and Public Health, discusses his paper on reducing the risk for vaccine preventable disease during the COVID-19 pandemic.

After surgery for Crohn’s disease, anti-tumor necrosis factor therapy was efficacious for preventing endoscopic recurrence without an increase in the incidence of adverse events, according to study results.

The Cleveland Clinic has appointed colorectal surgeon Conor Delaney, MD, PhD, as the new CEO and president of the institution’s Florida region. It was the top story in gastroenterology last week.

Patient preference favoring treatment discontinuation was improved during treatment with Entyvio or Stelara compared with anti-TNF therapy in patients with inflammatory bowel disease, according to study results.

High expression of ACE2 and TMPRSS2 in the small intestines may support gastrointestinal-correlated replication of SARS-COV-2, according to a study published in Gastroenterology.